Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Achieves Most Important Milestone Yet with Submission of IND Application for Phase 2a Clinical Trial

  • Tryp Therapeutics on September 22 submitted an IND application to the FDA to evaluate its oral formulation of synthetic psilocybin, TRP-8802, in a Phase 2a clinical study
  • The study seeks to evaluate TRP-8802 for the treatment of patients with eating disorders and will enroll 10 patients
  • According to Tryp Chairman and CEO, the submission is the first of several IND filings the company intends to make in the coming months
  • Tryp is also preparing for Phase 2b clinical trials, which will evaluate its proprietary drug candidate, TRP-8803

During a recent investor presentation, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing novel bioscience solutions for conditions with high unmet need, expressed its expectation to initiate at least two Phase 2a clinical trials in Q4 2021 (https://ibn.fm/H85KV). The trials, to be conducted at the University of Florida under the guidance of Dr. Jennifer Miller, a pediatric eating disorders expert and the trials’ principal investigator, will evaluate TRP-8802, Tryp’s oral formulation of synthetic psilocybin, in combination with psychotherapy.

The company announced September 22 that it had submitted to the US Food and Drug Administration (“FDA”) an Investigational New Drug (“IND”) application to evaluate TRP-8802 in the Phase 2a study for the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.